Key United States Patent Granted For The Treatment Of Heart Diseases, Stroke And Other Vascular Conditions
27. Oktober 2015 21:07 ET
|
Mesoblast
NEW YORK and MELBOURNE, Australia, Oct. 27, 2015 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB) (USOTC:MBLTY) today announced that the United States Patent and Trademark Office (USPTO) has granted a...
Phase 2 Trial Results Show Mesoblast Cell Therapy Has Greatest Cardioprotective Effect In Patients With Advanced Heart Failure
29. September 2015 21:10 ET
|
Mesoblast
NEW YORK and MELBOURNE, Australia, Sept. 29, 2015 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX: MSB; USOTC:MBLTY) today announced that additional Phase 2 trial results of its lead product candidate for...
Mesoblast Unveils Path to Bring Its Key Products to Market
25. August 2014 20:27 ET
|
Mesoblast
NEW YORK and MELBOURNE, Australia, Aug. 25, 2014 (GLOBE NEWSWIRE) -- Regenerative medicine company Mesoblast Limited (ASX: MSB; USOTC: MBLTY) today reported 2014 financial results and unveiled its...
National Institutes of Health and Mesoblast Enter Into Agreement for 120-Patient Trial In End-Stage Heart Failure
06. August 2014 20:57 ET
|
Mesoblast
NEW YORK and MELBOURNE, Australia, Aug. 6, 2014 (GLOBE NEWSWIRE) -- Regenerative medicine company Mesoblast Limited (ASX: MSB; USOTC: MBLTY) today announced the signing of an agreement with the United...
Mesoblast's Cell Therapy Strengthens Native Heart Function In Patients With End-Stage Heart Failure on Assisted Circulatory Support
18. November 2013 18:14 ET
|
Mesoblast
NEW YORK and MELBOURNE, Australia, Nov. 18, 2013 (GLOBE NEWSWIRE) -- Patients with end-stage or New York Heart Association (NYHA) class IV heart failure who receive a surgically implanted left...
Mesoblast's Mesenchymal Precursor Cells Induce Functional Recovery in Ischemic Stroke Model
11. November 2013 06:00 ET
|
Mesoblast
NEW YORK and MELBOURNE, Australia, Nov. 11, 2013 (GLOBE NEWSWIRE) -- Regenerative medicine company Mesoblast Limited (ASX:MSB) (USOTC:MBLTY) today announced positive preclinical trial results which...
Mesoblast Receives Clearance to Begin Phase 2 Clinical Trial of Mesenchymal Precursor Cells in Diabetic Nephropathy
25. Juni 2013 21:12 ET
|
Mesoblast
NEW YORK, N.Y., June 25, 2013 (GLOBE NEWSWIRE) -- Key Points:∙ Mesoblast has received ethics approvals to begin a clinical trial of its proprietary allogeneic, or “off-the-shelf”,...
Mesoblast Receives FDA Clearance for Phase 2 Clinical Trial of Mesenchymal Precursor Cells in Patients With Active Rheumatoid Arthritis
29. Januar 2013 20:25 ET
|
Mesoblast
Key Points:
Mesoblast receives clearance from United States Food and Drug Administration (FDA) to begin Phase 2 trial of proprietary allogeneic, or "off-the-shelf", Mesenchymal Precursor Cells...